Frontiers in Immunology (Oct 2021)

A Humanized Mouse Strain That Develops Spontaneously Immune-Mediated Diabetes

  • Sandrine Luce,
  • Sandrine Luce,
  • Sophie Guinoiseau,
  • Sophie Guinoiseau,
  • Alexis Gadault,
  • Alexis Gadault,
  • Franck Letourneur,
  • Patrick Nitschke,
  • Marc Bras,
  • Michel Vidaud,
  • Pierre Charneau,
  • Etienne Larger,
  • Etienne Larger,
  • Maikel L. Colli,
  • Decio L. Eizirik,
  • Decio L. Eizirik,
  • François Lemonnier,
  • François Lemonnier,
  • Christian Boitard,
  • Christian Boitard,
  • Christian Boitard

DOI
https://doi.org/10.3389/fimmu.2021.748679
Journal volume & issue
Vol. 12

Abstract

Read online

To circumvent the limitations of available preclinical models for the study of type 1 diabetes (T1D), we developed a new humanized model, the YES-RIP-hB7.1 mouse. This mouse is deficient of murine major histocompatibility complex class I and class II, the murine insulin genes, and expresses as transgenes the HLA-A*02:01 allele, the diabetes high-susceptibility HLA-DQ8A and B alleles, the human insulin gene, and the human co-stimulatory molecule B7.1 in insulin-secreting cells. It develops spontaneous T1D along with CD4+ and CD8+ T-cell responses to human preproinsulin epitopes. Most of the responses identified in these mice were validated in T1D patients. This model is amenable to characterization of hPPI-specific epitopes involved in T1D and to the identification of factors that may trigger autoimmune response to insulin-secreting cells in human T1D. It will allow evaluating peptide-based immunotherapy that may directly apply to T1D in human and complete preclinical model availability to address the issue of clinical heterogeneity of human disease.

Keywords